Compare Johnson & Johnson (JNJ) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Quantumscape Corp — how do they compare? Johnson & Johnson trades at $260.35 (market cap $626.09B), while Quantumscape Corp trades at $6.33 (market cap $3.90B). The key difference: Johnson & Johnson is far larger — about 160.5× Quantumscape Corp's market cap, and Johnson & Johnson pays a 2.06% dividend while Quantumscape Corp pays none. Which is the better fit depends on your goals.
| JNJ | QS | |
|---|---|---|
Market Cap | $626.09B | $3.90B |
Volume | 6,156,228 | — |
Sector | Health | Consumer Cyclical |
52-Week High | $267.24 | $18.44 |
52-Week Low | $172.78 | $4.89 |
Enterprise Value | $654.37B | $3.11B |
Dividend Yield | 2.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.
Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.
QuantumScape trades at $6.34, up 2.42% today, with a bullish technical signal but mixed sentiment. The company remains pre-revenue, reporting a net loss of $435.05M in 2025, with negative ROE and ROA. Recent earnings showed beats on EPS estimates, but commercialization timelines have been delayed to 2029, fueling investor skepticism.
The outlook hinges on successful battery technology commercialization by 2029, presenting high-risk, high-reward potential. Key risks include execution delays, intense competition, and reliance on financing. Analyst consensus is cautious, with no buy ratings, reflecting significant uncertainty around the company's path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
